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Pretreatment of L1210 cells with methotrexate has been 
shown by E, Cadman et al to enhance intracellular accumulation 
of 5-fluorouracil and the formation of metabolically active 
fluoropyrimidines, Sequential treatment with methotrexate and 
5-fluorouracil resulted in synergistic cytotoxicity. These 
effects of methotrexate were correlated with increased intra¬ 
cellular levels of PRPP(5-phosphoribosyl-l-pyrophosphate), the 
cofactor required for the conversion of 5-^luorouracil to 
5-fluorouridine-5*-monophosphate(FUMP), Methotrexate is a 
potent inhibitor of de novo purine synthesis and it is likely 
that methotrexate’s anti-purine effect resulted in the increased 
PRPP levels and therefore in synergism with 5-^luorouracil, 
The anti-purine effects of 24 cytotoxic agents were measured 
l4 
by quantitating incorporation of 1- C-glycine into purine 
bases. Possible synergism between each of these agents and 
5-fluorouracil is discussed based on the agents’ mechanisms 
of de novo purine synthesis inhibition. 
It was found that de novo purine synthesis progressively 
decreased from peak values in early log phase grow’th to/N-/ 
of the maximal level during late log and plateau phase growth 
of L1210 cultures. Increasing concentrations of exogenous 
hypoxanthine, a substrate in the salvage pathway of purine 
biosynthesis, were shown to progressively decrease de novo 
purine synthesis, making increased utilization of salvage 
purine synthesis along the growth curve one possible explan¬ 
ation for the observed decline in de novo purine synthesis. 
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A reduced rate of de novo purine synthesis secondary to length 
ening of the cell cycle from early to late log phase growth 
is discussed as a second explanation. Finally, a progressive 
decrease in cell volume with increasing culture density re¬ 
sulting in a need for reduced overall purine synthesis to main 
tain the required intracellular purine nucleotide concentra¬ 
tions is discussed as a third possible explanation for the 
decrease in de novo purine synthesis. The anti-purine effects 
of cytotoxic agents must be interpreted in the light of this 
natural progressive decline in de novo purine synthesis 
during exponential cell growth. 
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In treating cancer with cytotoxic drugs, clinical trials 
have shown that combinations of drugs generally result in better 
tumor response and patient survival than does single agent 
chemotherapy. Until recently these drug combinations were 
most often chosen on the basis of different proposed sites 
of drug action, different toxicity or simply empirically. 
Rarely has sequential drug therapy been designed from known 
biochemical parameters that would facilitate effective drug 
activation or other advantageous interactions between drugs 
or between natural metabolites and drugs. Certain sequential 
drug combinations have demonstrated synergism in inhibiting 
the growth of animal tumors(l), and the biochemically rational 
design of sequential drug therapy has become of interest to 
many investigators. 
Methotrexate and 5-f’luorouracil have been used success¬ 
fully both singly and in combination in treating many human 
neoplasms including breast and colon cancer(2), Ed Cadman 
et al have shown that methotrexate pretreatment of L1210 
murine leukemia cells in concentrations which produced near 
maximal inhibition of dihydrofolate reductase, enhanced intra¬ 
cellular accumulation of 5“f‘luorouracil(5-fold) and increased 
5-fold the formation of the 5-fluorouracil nucleotides, FUMP, 
FUDP, FUTP and FdUMP, These alterations correlated with 
synergistic cytotoxicity. In cells pretreated with methotrex¬ 
ate in concentrations between 0,lpiM and lO^M, intracellular 
5-phosphoribosyl-l-pyrophosphate(PRPP) pools were increased 
between 2 to 8 times over control values. The increases in 
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PRPP levels and in 5-fluorouracil accumulation could be pre¬ 
vented by the addition of leukovorin(N^-formyltetrahydrofolate) 
in concentrations which rescued cells from the inhibitory 
effects of methotrexate. If the PRPP pools were reduced fol¬ 
lowing methotrexate pretreatment by adding hypoxanthine which 
uses PRPP in its conversion to inosone monophosphate(IMP), the 
intracellular accumulation of 5-fluorouracil was not enhanced. 
These observations indicate that the enhanced 5-Tluorouracil 
accumulation within L1210 cells following methotrexate pre¬ 
treatment resulted from methotrexate's anti-purine effect 
which led to increased PRPP levels. The augmented PRPP levels 
produced by methotrexate were most likely the result of de¬ 
creased PRPP utilization in de novo purine synthesis and de¬ 
creased endproduct inhibition of PRPP synthetase by the re¬ 
duction in the purine nucleotides. The augmented PRPP pools 
were then able to be utilized in the conversion of 5-f’li^oro- 
uracil to 5“f‘luorouridylate(5FUMP) by orotate phosphoribosyl- 
transferase, the rate-limiting step in 5-fluorouracil intra¬ 
cellular metabolism(4). This is the primary reaction regula¬ 
ting the rate of intracellular 5-f'luorouracil accumulation. 
Methotrexate pretreatment of L1210 cells then incubated with 
5--fluorouracil resulted in a 5-i'old increased incorporation 
of 5-fluorouracil into RNA and in synergistic cell death 
as determined by soft agar cloning. Methotrexate pretreat¬ 
ment not only inhibits de novo purine synthesis leading to 
increased PRPP levels, but it also inhibits thym.idylate(dTMP) 
synthesis. 5-Tluorouracil, in one of its metabolically active 
forms, 5-fluoro-2'-deoxyuridine-5 *-monophosphate(5-FdUMP), 
... ' ' 
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also inhibits thymidylate synthesis by inhibiting the enzyme, 
thymidylate synthetase. Since the increased formation of 
5-FdUMP is unlikely to substantially increase the inhibition 
of thymidylate synthesis induced by methotrexate pretreatment, 
the likely mechanism of methotrexate - 5**flT-iorouracil syner¬ 
gistic cytotoxicity is the enhanced incorporation of the 
metabolite fluorouridine triphosphate(FUTP) into RNA(3). 
This proposed mechanism of methotrexate - 5-TluoJ^ouracil syn¬ 
ergism was tested in monolayer, cultures of human colorectal 
adenocarcinoma, HCT-8 cells. Sequential treatment with metho¬ 
trexate and 5“Tluorouracil resulted in a 3-fold increase in 
total intracellular 5-Tluorouracil accumulation, increased 
PRPP pools associated with enhanced 5-Tluorouracil metabolism, 
and synergistic inhibition of human colorectal tumor cells' 
clonal growh:h( 5* 6). 
The hypothesis of Cadman et al is that methotrexate 
enhances the metabolism of 5-i’l'uorouracil to fluoronucleo- 
tides which are incorporated into RNA, by inhibiting de novo 
purine synthesis. Other inhibitors of de novo purine synthe¬ 
sis, therefore, might prove to be similarly synergistic with 
5-fluorouracil. The purpose of this work was to quantitate 
the degree of de novo purine synthesis inhibition by several 
purine and pyrimidine analogs and antagonists, nucleosides 
and other cytotoxic agents by measuring the amount of 1- C- 
glycine incorporated into adenine and guanine. Additional 
work performed by Cadman et al investigated 5-fluorouracil 
intracellular accumulation, PRPP pools, fluoronucleotide 
levels and cytotoxicity resulting from sequential treatment 
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of L1210 cultures with several anti-purine agents and S-fluor- 
ouracilc The combined investigations were performed to 
determine whether cytotoxic synergism of 5-Tluorouracil and 
another anti-tumor agent was related to the agent's ability 
to inhibit de novo purine synthesis. In addition, this 
study investigates the relationship between the growth density 
of L1210 suspension cultures and the rate of de novo purine 
synthesis, examining the purine salvage pathway as a possible 
alternative method of purine synthesis at high culture den¬ 
sities, Cell cycle length and cell volume are also dis¬ 
cussed as factors influencing the rate of de novo purine 
synthesis. 
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MATERIALS AND METHODS 
Cells 
L1210 murine leukemia cells with a doubling time of 
10 to 12 hours were maintained as stationary suspension cul¬ 
tures in Fischer's glycine-free medium plus 10^ horse serum 
and were grown at 37®C in a 5% CO2 atmosphere. The stocks 
were diluted twice weekly and monthly cultures for myco¬ 
plasma contamination were negative. For each experiment 
testing a proposed anti-purine agent, cells were inoculated 
at 1-2 X lO^cells/cc and were harvested in the logarithmic 
phase of growth, generally at 2-5 X lO^cells/cc. Staining 
with trypan blue demonstrated^ 99% viability until cultures 
entered plateau phase. After 120 hours in culture, viability 
was reduced to < 70%(7). Cells were counted with a model 
ZBI Coulter Counter(Coulter Electronics, Inc,, Hialeah, FL). 
Drugs 
1-^^C-glycine(20mCi/mmole) which was used to evalu¬ 
ate de novo purine synthesis was obtained from the New Eng- 
1U- 
land Nuclear Corporation(Boston, MA), 8- C-hypoxanthine 
(56mCi/mmole) which was used in assessing the purine sal¬ 
vage pathway of L1210 cells was also obtained from the New 
England Nuclear Corporation(Boston,MA), Methotrexate, N- 
(phosphonacetyl)-L-aspartate(PALA), vincristine, 5~azacyti- 
dine and 3-deazauridine were provided by the Drug Development 
Branch of the National Cancer Institute, Bethesda, MD. 
Pyrazofurin was provided by Lilly Co.(Indianapolis,IN). 
All other compounds were purchased from Sigma(St, Louis,MO), 
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Growth Curve 
Logarithmically growing L1210 cells were inoculated in¬ 
to Fischer's medium plus 10% horse serum to achieve a concen¬ 
tration of 1 X lO^cells/cc. Aliquots of lOcc were trans¬ 
ferred to sterile culture tubes(3 tubes/time point). At 24- 
hour intervals, the tubes were carefully agitated and 1-cc 
aliquots were each diluted with 9cc of 0,9% NaCl, The cells 
were dispersed with gentle pipetting and cell numbers were 
determined with the ZBI Coulter Counter, 
De Novo Purine Synthesis Determination 
14 
The incorporation of 1- C-glycine into the purine 
bases of nucleic acid was used as a measure of de novo pur¬ 
ine synthesis. By a modification of Henderson's technique 
(8), lOOcc aliquots of L1210 cells at various phases of sus- 
14 
pension growth were incubated with 1- C-glycine for 2 
hours. In some experiments, cell cultures of 2-5 X 10-^cells 
per cc were incubated with anti-tumor agents for 1-2 hours 
14 
before the 1- C-glycine was added. The cells were centri¬ 
fuged at 1000 X g for 5 mins, and were washed in cold phos¬ 
phate buffered solution(PBS) with ImM glycine(unlabelled) 
three times. The supernatant was discarded and the cell pel¬ 
let was incubated with lo5cc of IMHCIO^^ at lOO'^C for 1 hour 
to depurinate the nucleic acids. Following centrifugation 
at 1000 X g for 10 mins,, the acid soluble supernatant was 
treated with 4N KOH to precipitate out the perchlorate salt. 
The supernatant, containing free purine bases, was neutral¬ 
ized with HCl and was analyzed by high pressure liquid 
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chromatography(HPLC) on a Partisil ODS-2 column(Whatman, Inc,, 
Clifton, NJ) eluting with a O.IM sodium acetate buffer(pH 5»5) 
and acetonitrile as a linear gradient from 0 to 7.5^ over 30 
mins, Nonradiolabelled adenine and guanine were used as 
markers to determime column retention times: Void volume 
containing glycine that was not incorporated into purine 
bases, ^ 4—7 mins,. Guanine ^ 12 mins, and Adenine ^ 38 
mins. Absorbance was recorded at 254 and 280nm, 0o5nil 
fractions were collected and the radioactivity was quantita¬ 
ted, The amount of radiolabel incorporated into adenine and 
guanine was calculated as pmol/lO^cells/hour, was expressed 
as a percentage of control and reflected the de novo purine 
synthesis rate for each experimental condition. The control 
cultures for each study were harvested for testing at the 
same culture density and v/ith the same nutritional status 
as the experimental cultures. 
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RESULTS 
Effects of Anti-tumor Agents on de novo Purine Synthesis 
The effects of 24 anti-tumor agents on the incorpor- 
14 
ation of 1- C-glycine into purine bases are shown in Table 1 
and in Figure A, In general, the purine analogs and antagon¬ 
ists such as hypoxanthine, inosine, adenosine, tubercidin 
and 6-thioguanine were found to be more potent inhibitors 
of de novo purine synthesis than were the pyrimidine analogs 
and antagonists such as 3-deazauridine, pyrazofurin, PALA, 
Ara-C, thymidine and 5-azacytidine. The RNA and protein syn¬ 
thesis inhibitors, actinomycin and cycloheximide respectively, 
were also found to significantly reduce de novo purine syn¬ 
thesis. 
Effects of Culture Density on de novo Purine Synthesis 
It was observed that the ability of an anti-tumor 
agent to inhibit de novo purine synthesis was dependent on the 
density of the culture that the experimental cells were harves¬ 
ted from. Table 2 illustrates that, in the case of 5--i*luoro- 
uracil, the anti-tumor agent could inhibit de novo purine 
synthesis to a nearly identical percentage of control given 
the same experimental culture concentration. Seen in the 
case of methotrexate, however, is an inverse relationship 
between culture density and the degree to which this potent 
anti-purine agent can inhibit de novo purine synthesis. The 
14 
control value for the amount of 1- C-glycine incorporated 
into adenine and guanine in the methotrexate study per¬ 
formed at a density of 1.2 X lO-^cells/cc was 25.5pinoles of 
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1- C-glycine Incorporation into Purine Bases 






into Adenine and 
Guanine/lO°cells/hr 
(% of control + 2,1%) 
Hypoxanthine 3 10 13.0 
Inosine 3 10 9.4 
Adenosine 3 10 20.7 
6-mercaptopurine 3 5 58.7 
6-thioguanine 3 5 15.9 
Virazole 3 10 39.1 
Tubercidin 1.5 10 17.4 
MMPR 3 2 61.0 
Pyrimidine AnalOi2:s 
Ara-C 3 1 84.8 
Thymidine 3 100 72c5 
Pyrazofurin 3 5 93.8 
5-azacytidine 3 30 62.6 
5-f’luorouracil 3 100 20.7 
5-fluorouridine 3 100 26. 1 
5-i‘luorodeoxyuridine 3 100 53.3 
Others 
Hydroxyurea 3 100 90.0 
Methotrexate 3 10 11.3 
Leukovorin 3 1000 108.2 
Vincristine 3 10 15.2 
Actinomycin D 3 10 g/ml 8.7 
Cycloheximide 3 10 10.9 
Azaserine 3 10 14.1 
L-alanosine 3 2 79.0 
PALA 84.8 
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Table 1 (continued) 
Abbreviations: MMPR, 6-methyl-inercaptopurine ribonucleoside; 
Ara-C, 1-^-D-arabinofuranosylcytosine; PALA, N-phosphonacetyl- 
L-aspartate. 
14 
The control value of moles of 1- C-glycine incorporated into 
adenine and guanine/lO^cells/hr varied with the culture den¬ 
sity and position of the control cells on the growth curve. 
For middle log phase cells at 3 X 10-^cells/cc, the control 
. 14 
value was 9.7o ± 2.45 pmoles 1- C-glycine incorporated into 
adenine and guanine/lO^cells/hr, The of control" values 
for the anti-tumor agents represent the amount of de novo 
purine synthesis occurring in the presence of the anti-tumor 
agents relative to the control cultures. These "% of con¬ 
trol" values were reproducible within + 2,1^ when the agents 
were tested in duplicate. 
Table 2 
Drug Concentration Cell Culture 
14 
1- C-elvcine into 
UM) 
/ 
Concentration Adenine and Guanine 
(XlO-^cells/cc) % of Control + 2.1% 
5-fluorouracil 100 1.2 15.9 
5-fluorouracil 100 1.3 20.7 
Methotrexate 10 1.2 16.5 
Methotrexate 10 6.0 50.0 
As in Table 1, 14 the control value for the amount of 1- C-glycine 
incorporated into purine bases varied with the culture density. 
For mid-log cells(3 X lO^cells/cc) the control value was 9.76 
21 2.45pmoles 1- C-glycine into adenine and guanine/lO°cells/hr, 
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Figure A Inhibition of de novo Purine Synthesis by Cytotoxic Agents 
- MMPR (2;aIVl) 
6-mercaptopurine 
Virazole (10;uM) 
— Adenosine (10;uM) 
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Mean (100^) Control Rate = 9.7^ ± 2.45 pmoles 1-^^C-glycine 




■ frtnO ^ ) »Xi*5iiSTiV *- 
(WuOi) s^n!i.aox^sbA 
Ji/r;0-i >0 ? , -r 
'■; ?/'. 
(M/uyOi) nibiaiscJyT -- 
} 3aXn3iv:^oi.f{t-3 —^ 
(f'Z'.OrJ Br.ldfasxaqxH ——— 
' MuO f) fttii a on I — 
-1-1-f—r-|-1--I-f-f 
C'P GB 0^ Oo 0^ 0^ cc OS 01 ( 
iioaii/otoi/Xl-S. _ ' 
aaoA t<r.ibl^. ^-zv,^ (M^COl^ ^Kti J:l*u»onowXl-?^ “ 
(M^OO!: ) SiUXx'X.W'cX'^^ai* S-r.-ioi/Xt-^ - "■ ....— 
( M£a,0 C ) £■ r: L b 1V t S jS v" .3i?"-,y _ 
(SfsxO 01^ sn ; t': r, C ___ _ 
; Mul) _ _._,,,_«*.,,,ii^ 
; ' i'i 'lij'!: o a s'r/’^ _ 
i.j'IjnOC ’X I I ! t 1 1 i I I-j.-,|-j-j-j,-h- 4-h-—h— 
00 i 0^-- 03 07 ^ Oc Oi Q4 OC OS 01 ' 
'■ X.4\'V ,p : ) XT nX D'^dOivl ^oA ^ _ 
(MK0i:> afeX^UxaitoIaY^J __ 




(Mt;S) sni 3ocislE- J ______ 
(Miv^) AZA^__ 
li'fiiu.OOI) 34i‘li/TCX0'li)\Jtir ■___ 
■ . i ', i ' ■ ——— „....«,.„..,....,_..,.„w.   
« »;rsH loi^noO (*^00:) ns»l' 
,’X^\,gIX9o'-Oi\aiain;?uC -r dnlftabA olni 
16 
l4 / 6 / 
1- C-glycine/10 cells/hr. The control for the methotrexate 
study at a density of 6 X 10-^cells/cc was 3.^pnioles incor¬ 
porated into adenine and guanine/lO^cells/hr, It therefore 
appeared that the amount of de novo purine synthesis de¬ 
creased as the density of L1210 cultures increased and that 
this decline in de novo purine synthesis influenced the ap¬ 
parent anti-purine potency of methotrexate. 
Figure B depicts the growth curve of L1210 cells over 
a 120 hour period. The cells grow exponentially to a culture 
concentration of approximately 5.5 X 10-^cells/cc at which 
the plateau phase of growth begins. Table 3 and Figure C 
show the relationship between culture density and the rate 
lil 
of de novo purine synthesis defined as the amount of 1- C- 
glycine incorporated into adenine and guanine in a 2 hour 
period. It was found that the rate of de novo purine syn¬ 
thesis decreases steadily as the culture density of L1210 
cells increases. As seen in Figure C, the amount of de novo 
purine synthesis progressively decreased to15^ of the 
early log phase level(100%), even in the face of exponential 
cell growth. During logarithmic cell growth, DNA and RNA 
synthesis precede actively. Since the rate of de novo pur¬ 
ine synthesis clearly diminishes along the upward swing of 
the growth curve, it seemed possible that the salvage path¬ 
way of purine biosynthesis might provide a portion of the 
purine nucleotide pool required for the actively dividing 
cells. 
To examine whether s: Iv^^ge purine synthesis could 
account for the decline in de novo purine synthesis along 




T*ao^ .:£rt\pXit5 OiXtniDxI^-:) -X 
c. A.i.; Lso^OX X to \:tiart»tj a t» 
. :»i,*^0Z'' ^ni:;;iJ0^ tiu?. ©nlfUfcj* otni batartoq 
% ‘ J'r." ■' ?.’'''t' '4 oven 3fc I -' vi'ii(jS 'iilX tAfit 
CA£. V ' ' ‘ ^ S. ' -•-3 CZS.Xi *> a-fi 
fi.-,n •-. ' ’f s/'.'•*’ fT's or.inij^ . v*!’: •>!) ni <*nXXo#t> siifS 
.,13X0'2 CIT-Jin 1 -j;’-057 :.ni-..'--itn^a tnrxiiq 
,.,r. : •• ■:'V£ o/'x ':7 e eiL3i^ 
., .-, ■' ^ o ^. T ,tr‘7i’X*q Ti/ort OSi a 
; !>;■ ^ •':r©./if£nx\>-iX'!-f6 '^0 fTotfMii’aawxoi} 
■ :. i:~z ^ fl’vvo'X^ ‘»aU'{tq tfss^fllq •rft 
. -. il^ = r.JBd qi ft ./W9ft8 
L^. .. ..^ - , ,. 3ir-'!r:-f>nvj=: ^nirujq evon at to 
,vt % - A ■.•• .i-L..-; •j.'-Z vh- /.v:0410arcJ •5ini:o\^X3 
. .,.y.^., .0 : _* <i5yf .boiioq 
■■ !L12 i- ^ ■^LJiAS'.ra ae^C'itcosb »lemd^‘ 
i •• t., ni .ass.-a-xanl 3L£«o 
w*1*T I j ■■’"•■- ' ' 7c?5 3v-.Mi.' ^ ivi aa'S'i'^o^o; aia'«itiJ'nY8 •fltl'Xi/Q 
lEi jnanQctx^’ to *»*.*'/'*■ vi'. ::i no'/f? *vdX uaart'j ^pX >£l'i48 
AV'H f- -r Av;c , ■>jf>i7'27j : jo Gx-nri-rins-^oi initvG .iitw€rr^ XX#o 
-•114 vV'<:rr r,t: to ■••cT^'T '3'^niS .\;X^vX)o« atuioa^u, i^taaiUtcvca 
t-'. ^«tX'V3 -Mid pirtoX^ 3©^(?..rniinib oi^adtetxa aai 
~‘tifaq 9^av£j^:< •^.•■’‘ -tAv* ':’ifJ233'0q o»tri»ea Xi ,ovn[i^a alwo'iia •rtJ' 
d/(^ to noit^oq s ab^voreq Tn^..:r to 




blijoo lioaricXirtd anX'lwq *» ':*i't3’«;'w iri-njac* OT 
^59X6 sXA'{3 ov<5<t ifl.v •^i 3/tiXoob aiXf *xot tftwoooi 
' //f#* aijotiaa^xa to ar.oixsqyn^acfsoo jjqia^^s'sonl ♦»v^a f^twoT^ 
17 
Figure B Grovrth Curve of L1210 Cell Cultures 
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a...rK»ls Ij’. jin:' ClSli to 
18 
■Pin-n-rp n L1210 Culture Concentration vs. Rate of de novo Purine 
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Table 3 L1210 Culture Density vs. Rate of de novo Purine Synthesis 
Early Log Mid Log Late Log Plateau 
)ells/cc X 10^ (0.3 - 1.2) (1.3 - 3.5) (3.6 - 5.6) ( 5.7) 
m Rate of 
novo Purine 




hypoxanthine were incubated with L1210 cell cultures. Hypo- 
xanthine is an intermediate of purine catabolism and can be 
utilized in salvage purine synthesis. Figure D shows that as 
the availability of hypoxanthine in the culture media increased, 
de novo purine synthesis was reduced to, at 10“-^M hypoxanthine, 
17% of control. The control value for de novo purine syn- 
. 14 
thesis was 10.2 pmoles 1- C-glycine incorporated into 
adenine and guanine/ lO^cells/hr without any exogenous hypo¬ 
xanthine in the media. The experiment was performed with 
L1210 cultures in log phase growth at a density of 4.0 X 10^ 
cells/cc. This relationship between the progressive decrease 
in de novo purine synthesis and increasing concentrations of 
exogenous hypoxanthine suggests that utilization of the sal¬ 
vage pathway of purine synthesis leads to reduced purine syn¬ 
thesis via the de novo pathway. 
The effects of increasing concentrations of exogenous 
14 
C- hypoxanthine on salvage purine biosynthesis was tested 
to demonstrate the existence of the enzymatic machinery 
needed for salvage purine synthesis in L1210 cells. Figure E 
14 
shows that a significant amount of C-hypoxanthine was in¬ 
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Figure D Exogenous Hypoxanthine vs, the Rate of de novo Purine 
Synthesis 
The control value for the rate of de novo purine synthesis with 
14 
no exogenous hypoxanthine in the media was 10,2 pmoles C-glycine 
into A+G/lO^ cells/hr. 
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C-Hyooxanthine vs. Rate of Salvage Purine 
S\TLthesis 
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. 
concentration of C-hypoxanthine was l;al\i or greater. This 
experiment was performed on log phase cells at a density of 
4,3 X lO^cells/cc, Figure E demonstrates that when the con¬ 
centration of exogenous hypoxanthine is in the range of 
the L1210 cells will utilize this substrate in salvage purine 
synthesis. Figures D and E together demonstrate that de novo 
purine synthesis progressively decreases as the salvage purine 
synthesis pathway is increasingly utilized which it will be if 
a suitable substrate such as hypoxanthine is present in suf¬ 
ficient concentrations. Therefore, one possible explanation 
for the observed decrease in de novo purine synthesis 
throughout the logarithmic and plateau phases of L1210 culture 
growth is increasing utilization of the salvage pathway of 
purine synthesis occurring as cell death and purine catabolism 
provide the necessary substrates for salvage purine synthesis, 
14 
Intracellular pools of 1- C-glycine in early and mid¬ 
dle log phase cultures were measured after cell cultures were 
l4 
incubated with 1- C-glycine for 24 hours. The amount of 
i / 6 • 
intracellular 1- C-glycine/10 cells within cultures harves¬ 
ted at 9,0 X lO^cells/cc and others at 3*8 X lO^cells/cc was 
not significantly different after 24 hours. Therefore, 
growth phase specific variations in intracellular glycine 
pools could not account for the decrease in de novo purine 
synthesis observed with increasing culture density. 
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DISCUSSION 
Effects of de novo Purine Synthesis Inhibitors on 5-Fluorouracil 
Metabolism and Cytotoxicity 
In conjunction with the above work which quantitated 
the degree to which anti-tumor agents inhibited de novo pur¬ 
ine synthesis, Cadman et al. examined the effects of five of 
these anti-purine agents on 5-fluorouracil metabolism and 
cytotoxicity. The results of the influence of methotrexate, 
tubercidin, 6-methylmercaptopurine ribonucleoside (MIllPR), 
azaserine and L-alanosine on the intracellular accumulation 
of 5-^luorouracil and on PRPP levels are summarized in 
Table 4 (9). 
As noted previously, the effect of the folate analog, 
methotrexate, in increasing the intracellular accumulation of 
5-fluorouracil is thought to result from the inhibition of 
de novo purine synthesis by methotrexate. Methotrexate is a 
tight-binding inhibitor of dihydrofolate reductase. It was 
found to be a potent inhibitor of de novo purine synthesis, 
reducing it to 11.3?^ of control. Methotrexate prevents the 
conversion of dihydrofolate to 5*10-methylenetetrahydrofolate 
(CH2THF), thereby depleting the CH2THF pools.(See Figure F) 
CH2THF is required for the conversion of deoxyuridylic acid 
(dUMP) to thymidylic acid(dTMP) and methotrexate therefore 
inhibits thymidylic acid synthesis in the de novo pyrim.idine 
pathway. The CH2THF pools are also necessary for methyla- 
tion at two steps in de novo purine synthesis and therefore 
purine synthesis is significantly reduced with methotrexate. 
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Figure F Effect of Methotrexste on Thyr.idylate S^mthesis 
de novo pyrimidine 
synthesis 
CH^THF » 5*10 methylenetetrahydrofolate 
DKF - dihydrofolate 
DHFR “ dihydrofolate reductese 
^iTl] - Methotrexate 
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Table 4 Effects of Purine Synthesis Inhibitors on 5-Fluoro- 
uracil Accumulation and PRPP Levels (9) 
Drue: Concentration 
(pM) 
5-FU Accumulation PRPP 
(Treated/Control) 
Methotrexate 10 4.32 8 
MMPR 10 4.40 15.7 
Azaserine 10 3.00 15.0 





Tubercidin 10 Undetected 0.1 
In control cells, 5-fluorouracil accumulation was 
0.025pmoles/min»lO^cells and PRPP was 7± 1.2ng/l0^cells, 
Cell cultures were exposed to the drugs for 3 hours before 
evaluating 5FU accumulation and PRPP levels. 
MMPR - 6-methyl-mercaptopurine ribonucleoside. 
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(See Figure G), This two point inhibition of de novo purine 
synthesis leads to a build-up of PRPP due to decreased util¬ 
ization and to reduced feedback inhibition of the de novo 
pathway by purine nucleotide endproducts. Since PRPP syn¬ 
thetase is a regulatory enzyme inhibited by the purine end- 
products ( 10 ) , decreased purine synthesis results in in¬ 
creased PRPP synthesis and therefore in elevated intracell¬ 
ular PRPP levels. This PRPP is then available to enhance 
the conversion of S-i’luorouracil to leading to in¬ 
creased intracellular accumulation of 5-fluorouracil, Hypo- 
xanthine completely prevents the purineless state induced by 
methotrexate, a state which contributes to the lethal effects 
of methotrexate(11), However, both thymidine and a purine 
source are required by all cell lines examined to completely 
eliminate the cytotoxic effects of methotrexate(12). 
Tubercidin(7-deazadenosine) is phosphorylated to its 
active metabolite by adenosine kinase. In its active form, 
it inhibits PRPP synthetase(13) and therefore does not re¬ 
sult in increased PRPP levels nor in enhanced intracellular 
FUra accumulation. When L1210 cells, pretreated with metho¬ 
trexate, were incubated with tubercidin, the PRPP elevation 
and increased FUra accumulation seen with methotrexate were 
prevented(3). This suggests that de novo purine synthesis 
inhibition resulting in increased PRPP levels is the key 
effect of methotrexate in augmenting FUra accumulation. 
Another purine nucleoside analog, MMPR(6-methyl- 
mercaptopurine ribonucleoside), is also phosphorylated by 
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ENZYMES 
1, Amidophosphoribosyl tranferase 
2, Phosphoribosylglycineamide synthetase 
3, Phosphoribosylglycineamide formyltransferase 
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Figure G (continued) 
ENZYMES 
4. Phosphoribosylformylglycineamide synthetase 
5. Phosphorihosylaininoimidazole synthetase 
6. Phosphoribosylaminoimidazole carboxylase 
7. Phosphoribosylaminoimidazole-succinocarboxamide synthetase 
8. Adenylosuccinate lyase 
9. Phosphoribosylaminoimidazole-carboxamide formyltransferase 
10. IMP cyclohydrolase 
11. Adenylosuccinate synthetase 
12. Adenylosuccinate lyase 
13. IMP dehydrogenase 
14. GMP synthetase 
adenosine kinase and inhibits the rate-limiting enzyme of 
de novo purine synthesis, amidophosphoribosyl transferase(14). 
MMPR did elevate PRPP levels and enhanced FUra accumulation. 
Azaserine also increased intracellular PRPP levels and 
FUra accumulation. This anti-purine agent is a glutamine an¬ 
tagonist which inhibits de novo synthesis at the two steps 
requiring glutamine for amide transfer(15).(See Figure G) 
Inhibition of the first amide transfer catalyzed by amido¬ 
phosphoribosyl transferase probably leads to the increased 
PRPP levels and subsequent enhanced FUra accumulation. 
L-alanosine, an L-aspartate analog, competitively in¬ 
hibits the intracellular transport of L-aspartic acid and 
inhibits several enzymes involved in de novo purine synthesis 
as; 
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including adenylosuccinate synthetase, phosphoribosylamino- 
imidazole-succinocarboxamide synthetase, and L-glutamine 
synthetase(9)t Inhibiting de novo purine synthesis at the 
steps catalyzed by the above enzymes led to increased PRPP 
levels and to augmented FUra accumulation in the L1210 cultures 
treated with L-alanosine. 
The inhibitory effects of these 5 agents on de novo 
purine synthesis is summarized from Table 1 in Table 5» 
Table 5 Inhibition of de novo Purine Synthesis by Cytotoxic 
Agents 
Drug Exposure Concentration 1- C-glvcine into 
(hrs.) (piM) A+C/lO^cells/hr. 
of control + 2, 
Methotrexate 3 10 11.3 
^'IMPR 3 2 6l.O 
Azaserine 3 10 14.1 
Tubercidin 1.5 10 17.4 
L-alanosine 3 2 79.0 
Each drug had a significant inhibitory effect on de novo 
purine synthesis and each agent, except L-alanosine, inhib¬ 
ited both adenine and guanine synthesis equally. L-alano¬ 
sine inhibits adenylosuccinate synthetase which converts IMP 
to AMP, Thus, adenine synthesis is inhibited while the 
pathway from IMP to GMP is unaltered. The reduction in 
purine synthesis seen with L-alanosine was due entirely to 
decreased adenine synthesis. 
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To examine potential cytotoxic synergism between 
these 5 anti-purine agents 5-Tluorouracil, L1210 cultures 
were treated sequentially with an anti-purine drug and FUra 
and cytotoxicity was determined by soft agar cloning of the 
cells. The results are shown in Table 6 (9). 
Table 6 Viabil ity of L1210 Cells (9) 
DRUG 1 DRUG 2 uM(l) uM(2) hr(l) hr(2) ^Viability 
Control 0 0 0 0 0 100 
Methotrexate 0 10 0 4 0 60 
0 FUra 0 10 0 1 100 
Methotrexate FUra 10 10 3 — —> 1 10 
MMPR 0 1 0 4 0 100 
MMPR FUra 1 10 3 — —> 1 6 
Azaserine 0 6 0 4 0 77 
Azaserine FUra 6 10 3 — —> 1 10 
L-alanosine 0 10 0 4 0 106 
L-alanosine FUra 10 3 3 — —> 1 41 
The arrow(->) indicates that Drug 1 was given for 
the indicated time before adding Drug 2, Total drug exposure 
was 4 hours before cloning the cells in soft agar. 
Synergistic cytotoxicity was seen with the anti-purine agents 
which increased intracellular FUra accumulation. It therefore 
appears that pretreatment with anti-purine agents which results 
in increased PRPP levels, allows for increased activation of 
FUra to FUMP and for increased FUra accumulation, resulting, 
therefore, in enhanced cell killing. 
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This proposed mechanism of cytotoxic synergism is con¬ 
sistent with the findings of other investigators. MMPR in¬ 
creases intracellular PRPP levels and has been shown to en¬ 
hance conversion of 6-thioguanine(6-TG) and 6-mercaptopurine 
(6-MP) to their active inhibitory metabolites, 6-thioguanylic 
acid and thioinosinic acid, respectively(16,1?)« 
Guanine-Hypoxanthine 
6-MP + PRPP -rr-r-rr-—-- > thio-IMP f PPi (18) 
Phosphoribosyl transferase 
Guanine-Hypoxanthine 
6-TG + PRPP -rr-r—rr--r-> thio-GMP + ppi (19) 
Phosphoribosyl transferase 
Cadman et al, also examined the intracellular metabolites 
of FUra in L1210 cells pretreated with methotrexate(3»20) and 
MMPR(unpublished results). FUMP, FUDP, FUTP and FdUMP were all 
elevated above control values in proportion to the increase in 
total intracellular FUra accumulation. The increase in these 
metabolites probably occurred as a consequence of increased 
PRPP levels since the primary metabolic pathway for FUra is 
conversion to FUMP by orotate phosphoribosyltransferase, using 
PRPP as a co-factor. 
orotate 
FUra + PRPP -T-T-rr-77-1^ FUMP + PPi (4,21) 
phosphoribosyltransferase ’ 
The enhanced cytotoxicity observed following sequential 
treatment with an anti-purine agent and FUra may be the result 
of increased intracellular FdUMP and FUTP levels. FdUMP in¬ 
hibits thymidylate synthetase and FUTP is incorporated into 
RNA. Complete protection of mouse L cells from FUra cytotox¬ 
icity requires the presence of both thymidine and uridine in 
the media indicating that FdUMP and FUTP act together in 
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killing cells(22), 
This study illustrates how one category of anti-tumor 
agents, the de novo purine synthesis inhiibitors, can enhance 
the metabolic activation of another group of agents, in this 
case, the fluoropyrimidines. It also demonstrates one approach 
to designing biochemically rational sequential drug treatments 
in the search for synergistic tumor cytotoxicity. 
Effect of Cytotoxic Agents on de novo Purine Synthesis 
Ed Cadman et al. demonstrated that the anti-purine 
agents which enhanced the effects of FUra were those which led 
to increased intracellular PRPP levels. In addition to the 5 
agents discussed above, several other anti-tumor drugs with 
various mechanisms of action were found to inhibit de novo 
purine synthesis. 
Pyrimidines and Pyrimidine Analogs and Antagonists 
Ara-C(1-B-D-Arabinofuranosylcytosine) is a deoxycy- 
tidine analog, the active metabolite of which is the triphos¬ 
phate form, Ara-CTP. Ara-C exerts its cytotoxic effect 
through the inhibition of DNA polymerase, although incorpora¬ 
tion of Ara-C into DNA may be an important contribution to 
its anti-tumor action(23). In the presence of Ara-C, de novo 
purine synthesis was found to be 85^ of control. It is 
possible that inhibition of DNA polymerase with a concomitant 
decrease in DNA synthesis leads to a build-up of adenine and 
guanine nucleotides which then inhibit de novo purine synthesis. 
Increased intracellular concentrations of purine ribonucleo¬ 
tides have been found to inhibit the first committed step 
in de novo purine synthesis which is catalyzed by the enzyme 
amidophosphoribosyl transferase(24, 50), The increased purine 
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levels also inhibit phosphoribosyl pyrophosphate(PRPP) synthe¬ 
tase, the enzyme which supplies PRPP, an essential cofactor 
for amidophosphoribosyl transferase(10,51). Given this pro¬ 
posed mechanism for the inhibition of de novo purine synthesis 
by Ara-C, this agent would not be expected to enhance the cyto¬ 
toxic effects of FUra since no significant increase in PRPP 
levels would occur with the elevated purine nucleotide 
levels inhibiting PRPP synthetase. 
Thymidine(dThd) is a pyrimidine nucleoside which in¬ 
hibits ribonucleotide reductase in its triphosphate form(dTTP). 
Inhibition of this enzyme is thought to result from feedback 
inhibition by expanded dTTP pools and has been found to cause 
reduced dCTP levels and therefore decreased DNA synthesis(25). 
With decreased dCTP levels limiting DNA synthesis, an initial 
increase in purine ribonucleotide pools due to decreased util¬ 
ization may result. The observed reduction in de novo purine 
synthesis by 27.5% niay have been the result of unused end- 
products of purine synthesis feeding back and inhibiting 
amidophosphoribosyl transferase and PRPP synthetase. Thymi¬ 
dine has been shown to increase incorporation of FUra into 
RNA and to increase the cytotoxic effects of FUra, though the 
mechanism for this has not been well-defined(26), This drug 
sequence has been found to enhance the interference with 
ribosomal RNA processing that occurs when FUra is used alone(27), 
Pyrazofurin(4-hydroxy-5-B-D-ribofuranosylpyrazole-3“ 
carboximide) is a nucleoside analog which when converted to 
its monophosphate form by adenosine kinase, inhibits orotidy- 
late decarboxylase, the enzyme which converts orotidylate(OMP) 
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to uridylate(UMP) (28) in the de novo pyrimidine synthesis path¬ 
way. This results in reduced pyrimidine ribonucleotide and 
deoxyribonucleotide pools and in increased orotate levels as 
decreased UMP levels stimulate de novo pyrimidine synthesis(29). 
Pyrazofurin inhibited de novo purine synthesis only minimally, 
(93.8^ of control) but this slight decrease may have been sec¬ 
ondary to an increased utilization of PRPP in converting the 
elevated orotate pools to orotidylate. This effect of pyrazo¬ 
furin in increasing consumption of PRPP by orotate phospho- 
ribosyltransferase, will not only decrease de novo purine syn¬ 
thesis, but will antagonize the actions of FUra by decreasing 
FUra*s conversion to FUMP, the first step in the metabolic 
activation of FUra, Studies of the enzyme kinetics have re¬ 
vealed that the conversion of orotate to OMP is energetically 
more favorable than the conversion of FUra to FUMP(4), Cad- 
man et al, have examined the values for the conversion 
of FUra and orotate to their 5'phosphate nucleotides by oro¬ 
tate phosphoribosyltransferase in L1210 cells and found them to 
be 520piM and 12pM, respectively(3)o A.S. Bagnera, using 
Ehrlich ascites tumor cells, has shown that increased utiliza¬ 
tion of PRPP by phosphoribosyltransferases is a potent mechan¬ 
ism of de novo purine synthesis inhibition because the Kjyj for 
the phosphoribosyltransferases including orotate phosphoribo¬ 
syltransferase, is in the range of 5“40piM, while the Kj^for the 
amidophosphoribosyl transferase of de novo purine synthesis 
is ImM(lO). 
5-azacytidine is a cytidine analog which is incorpor¬ 
ated into RNA in the triphosphate form, 5-aza-CTP(31). 
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5-aza-CTP distorts the secondary structure of PwNA and the in¬ 
effective, fragmented nucleic acid is rapidly degraded into 
its component nucleotides(32), Taylor et al. demonstrated in¬ 
creased total intracellular nucleotide pools in Chinese Hamster 
cells after a 2 hour treatment with 5-azacytidine. They also 
found a 50% reduction in PRPP levels presumed secondary to 
feedback inhibition of PRPP synthetase by the increased purine 
nucleotide pools(32). In this study 5-azacytidine was found 
to reduce de novo purine synthesis to 62,6^ of control probably 
due to the degradation of faulty RNA molecules with the subse¬ 
quent liberation of ATP and GTP. Pretreatment of cultures with 
5-azacytidine would antagonize the cytotoxic effects of FUra 
because the decreased PRPP levels caused by 5-azacytidine would 
retard the conversion of FUra to its active metabolites. 
5-fluorouracil(FUra) is a pyrimidine analog, the active 
metabolites of which are 5-FdUMP and FUTP.(See Figure H) 5-FdUMP 
inhibits thymidylate synthetase, the enzyme which converts dUMP 
to dTMP, thus, treatment with FUra results in dTTP deprivation. 
The *'thymine-less death" is thought to occur as inadequate 
dTTP pools inhibit DNA synthesis leading to degradation of 
the fragmented pieces of DNA(33)» FUTP is incorporated into 
RNA and there inhibits the processing and maturation of RNA 
precursor molecules which are subsequently degraded. FUTP 
also causes an inhibition of ribosome formation, miscoding 
during mRNA translation and mismatching of tRNA*s and the 
appropriate amino acids(3^»35). The reduction to 20.7% of 
control for de novo purine synthesis found after treating L1210 
cells with FUra alone is probably the result of both the 
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Figure H Metabolic Conversion of 5-Fluorouracil v43) 
FUra — » FUMP- FUDP- 1 1 1 
V 








1. Orotate phosphoribosyltransferase 
2. Thymidine phosphorylase 
3. Uridine phosphorylase 
4. Uridine-cytidine kinase 
5. Thymidine kinase 
6. Ribonucleotide reductase 
7. Thymidylate synthetase 
"thymine-less" state and the production of faulty RNA molecules. 
Thymine deprivation leads to decreased DNA synthesis producing 
a build-up of purine nucleotides. The degradation of defect¬ 
ive RNA molecules contributes to elevating the levels of pur¬ 
ine nucleotides which inhibit de novo purine synthesis by 
feedback inhibition. 
5“fluorouridine(FUrd), also a fluorinated pyrimidine, 
is a precursor of both the active metabolites of FUra, FdUMP 
and FUTP, (See Figure H) Therefore both degradation of faulty 
RNA molecules and inhibition of thymidylate synthetase with 
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the subsequent production of fragmented DNA molecules would 
result from treatment with FUrd, De novo purine synthesis in 
the presence of FUrd was only 26,1^ of control probably be¬ 
cause, as with FUra, the purine nucleotides liberated from 
the nucleic acid breakdown inhibited de novo purine synthesis, 
5-fluoro-2'-deoxyuridine(FdUrd) is phosphorylated to 
FdUMP by thymidine kinase(36) and is cleaved to FUra by both 
thymidine and deoxyuridine phosphorylases(37). The primary 
metabolite of FdUrd is FdUMP which inhibits DNA synthesis by 
creating a thymine-deficient state, De novo purine synthesis 
was reduced to 53*3% of control with FdUrd probably as a re¬ 
sult of the build-up of purine nucleotides following decreased 
DNA synthesis and from degradation of DNA fragments. Some 
conversion of FdUrd to FUra may also have contributed to 
FdUrd*s anti-purine effect. 
Purine Analogs and Antagonists 
Hypoxanthine is a purine base which is converted to 
inosinic acid(IMP) by the purine salvage enzyme, hypoxanthine- 
guanine phosphoribosyltransferase. PRPP is the co-substrate 
in this conversion donating a phosphoribosyl moiety to hypo¬ 
xanthine, IMP is then converted to AMP and GMP which feedback 
and inhibit de novo purine synthesis. Treatment of L1210 
cultures with hypoxanthine decreased de novo purine synthesis 
to 13.0% of control by providing a substrate for the salvage 
pathway of purine biosynthesis. Because the salvage metabolism 
of hypoxanthine utilizes PRPP, hypoxanthine would be expected 
to antagonize the activation and therefore cytotoxic effects of 
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FUra, Cadman et al, found that adding hypoxanthine to L1210 
cultures pretreated with methotrexate prevented the methotrex¬ 
ate-induced elevation of PRPP levels and enhanced intracellular 
accumulation of FUra(3). 
Inosine is a purine nucleoside which inhibited de 
novo purine synthesis to 9.3^ of controlo Inosine can be 
hydrolyzed to hypoxanthine and the free ribose moiety by purine 
nucleosidase. Inosine may also be converted by purine nucleo¬ 
side phosphorylase to hypoxanthine and ribose-l-phosphate. 
Nucleoside 
Phosphorylase 
Inosine -Hypoxanthine + Ribose-l-Phosphate 
Pi 
H2O 
Inosine —-Hypoxanthine + Ribose (38) 
Purine Nucleosidase 
This hypoxanthine can then be converted to IMP by hypoxanthine- 
guanine phosphoribosyltransferase with PRPP acting as the 
phosphoribosyl donor, De novo purine synthesis is probably 
inhibited as the AMP and GMP formed from IMP feedback and in¬ 
hibit amidophosphoribosyl transferase and PRPP synthetase. 
Utilization of PRPP in salvaging hypoxanthine may also contrib¬ 
ute to the observed decrease in de novo purine synthesis(10). 
It has been shown that in cells such as L1210 cells which 
possess the enzyme purine nucleoside phosphorylase, inosine 
promotes the incorporation of FUra into RNA by providing a 
ribose-l-phosphate moiety v;hich converts FUra to FUrd(39,^0). 
FUra + Ribose-l-Phosphate -> 5-Fluorouridine 
Uridine 
Phosphorylase 
From FUrd, the activation of FUra proceeds to both FdUMP and 
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FUTP(See Figure H). Inosine, then, would be expected to en¬ 
hance the cytotoxic effects of FUra by providing not PRPP, 
but ribose-l-phosphate to activate FUra, 
Adenosine is a purine nucleoside which inhibited de 
novo purine synthesis to 20,7% of control. Adenosine can be 
converted to inosine by adenosine deaminase which, after met¬ 
abolism to hypoxanthine, can be used in salvage purine bio¬ 
synthesis, Adenosine can also be phosphorylated by adenosine 
r-' 
kinase to AMP which will feedback and inhibit de novo purine 
synthesis. As with inosine, adenosine can be catabolized to 
its respective purine base, adenine, by nucleoside phosphor- 
ylase producing ribose-l-phosphate which can convert FUra to 
FUrd, Adenosine suppresses de novo purine synthesis by con¬ 
version to both AMP and hypoxanthine, the latter which is sal¬ 
vaged to IMP, Adenosine has been shown to markedly stimulate 
the uptake and incorporation of FUra into the RNA of Novikoff 
hepatoma cells by providing the ribose-l-phosphate for activa¬ 
tion of FUra(4l), 
6-mercaptopurine(6-MP) is a hypoxanthine analog which 
inhibited de novo purine synthesis to 58.7% of control, 6-MP 
utilizes PRPP in its conversion to thio-IMP by hypoxanthine- 
guanine phosphoribosyltransferase(42), Thio-IMP is then con¬ 
verted to deoxy-thio-ITP and in this form may be incorporated 
into DNA, Thio-IMP prevents the conversion of IMP to AMP and 
GMP by inhibiting adenylosuccinate synthetase and IMP dehydro¬ 
genase, It also inhibits amidophosphoribosyl transferase by 
mimicking the effect of the natural purine nucleotides as 
negative feedback inhibitors(14 ), Thio-IMP's role as a pseudo- 
■ : ,:i >0 sixoTot’^d »o«Bri 
■ ■- ■ 'i,biaosl‘'V\ saiauq^fi al mtuoiivlA 
: ■ ’9h'.A .,.Lc’;-^lo'c ''r* -^'■, . OS 0* anlTUxj ovon 
- . ‘’£_''^’*' '^--•''i:f!j:e r> X-- 07 StmTH’^YfiOO 
^ftsTj/n i.-?:.''. j-.v; :. w»o<6.i -mj cfso ,»ni^7{texocpi,fi crt mBliodM' 
• >•• ■ ' '■ T 'Oitc ad oalA rtfio anlBOi^abA ^ai»oi{7ity£a 
[j[2Vf d'jtr.w <^A ot «Qptxiil 
lo-if.. 1 - j ,^.3- . 1. ,i)rUsOiti ffJ-N zh ,&i99iittvi9 
■I -*' jjiai'r. 'id ,3i'iir{isbQ ,«3eis<j fjnt'ji.cr •j''X3‘?5«qfi0*i 
’ r.j*:: rtorrivA f •#«odJ:'5 ‘^ixloubcnq daaX^ 
•-.iait.'.-. i:';.5 i*7i^uq r.vr.n &ib 960!a**iq<|t;^ eniaanBbA ^tnU^ 
'-’■ 'u.*;jjI . •?.ii •.^r;5xoq'trf rif,<! TAA. rfto^ od' rtoiaiav 
A 1 
' e 
-1 ::f -A-iiic: ot ,T,.c.i‘>: .-lifet BC'JaoasbA • .'?MI ot bajiBV 
• • .v,tp. s.iJ- siU’-I '>0 noti-:;ao^r^^6fTi boa t-Hatqy »rtt 
-• - '.1C-^-r-po "f.rr -iitt ^nicivocq 'Cd bIXoo mo7.:qoii 
,it4)jsrLm lo nolt 
•'J. ' L^rc gni ttu-cyocvn i- ni )^nJ'^A'xyo>q«o't3m-i 
.i:' u*r.'oo oJ“ 0i?!i,*r, rn-^e erri-it-'q’^'bvcn »& 6#ti<firOrti 
-vf. xcqvr' qo 7Wl-.<)xdi ot noia-t&vfioo atl ni aoalLldu 
ij >2i ‘iMI-oi/iT • (S4i)-«saPTt#i{*,ff<WtX^aodl^Oi1qaodq octltiaiT^ 
•j7:rT'-q-rrcni orto^- ax/^* ni brjs ot Jbet^ev 
Ld& qwr io ,:OTU'reVi''00 :>.tlt^V'»'Tq *aMI-oi:iT .Alia otni 
- -.y,i orr^ sBflferftnve 'id S3J0 
•:d 9 3BT3'l£nTi. .f’^odi'ioffqa • atxdtrixti ciXja tl .Baarsaa 
a* aofti.;o.s.xoxfc X^rr^n ant lo ro#!;!# tilt 
>ofM;,4aq 4 34 bXot •♦-i-il-otrt’? . (: ii^inoticfXrtnX jioadbftl tvlta^an 
40 
feedback inhibitor is thought to be the major site of inhib¬ 
ition for 6-MP because the fro thio-IMP in inhibiting amido- 
phosphoribosyl transferase is 4o4 X a concentration 
generally achieved in cell cultures and therapeutic regimens(42), 
6-IVIP Would be expected to compete with FUra for PRPP, the sub¬ 
strate both agents utilize for metabolic activation. 
6-thioguanine(6-TG) is a guanine analog which inhib¬ 
ited de novo purine synthesis to 15o9% of control. Like 6-MP, 
6-TG is converted to its monophosphate form, thio-GMP, by 
hypoxanthine-guanine phosphoribosyltransferase, utilizing 
PRPP as the phosphoribosyl donor. Thio-GMP acts as an allo¬ 
steric pseudofeedback inhibitor of amidophosphoribosyl trans¬ 
ferase, thus depressing de novo purine synthesis, Thio-GMP 
inhibits IMP dehydrogenase which converts inosinic acid(IMP) 
to xanthylic acid(XMP), Thio-GMP also inhibits the conversion 
of GMP to GDP by nucleot'ide monophosphokinase (42, l4), thus 
allowing the relative accumulation of GMP which will inhibit 
de novo purine synthesis by endproduct inhibition. 6-TG 
would be expected to antagonize the cytotoxic effects of FUra 
since both agents compete for metabolic activation by PRPP. 
Virazole(1-^-D-ribofuranosyl-l,2,4-triazole-3-carbox- 
amide) is a nucleoside analog which inhibits inosinate de¬ 
hydrogenase, the enzyme which converts inosinic acid to xan- 
thyic acid, the precursor of guanylic acid(GMP)(44). Vira¬ 
zole has been found to be structurally similar to guanosine 
in its crystalline state. Its active metabolite is virazole- 
5‘-phosphate and it is thought to be a substrate for nucleo¬ 
side kinase(44). Virazole decreased de novo purine synthesis 
_.f;, v,- 3». -TfoililAttJ. i^6<fba9\ 
ooio'R a.-i; Tf »/<.■ ^ay«a«af 'lot noiti 
'I : ^ j ,'»r“0:- X T^4i 0ii aseis-la.-tirt^ r^eoif ^'xoiqaodq 
• ,■-.’c-if.:i'- '-;::..-iw,i,t iXt3g&-qi 
- 4 •- .-f.r ..^ TO*" i-ftiy^ .sjaq.'no-^ o" ’:e.3o»^*« #(f tU uo^ 
■* ^\ ■ 
^.i: 2 
Oi 5'iXoij:;! j": .i'V 8.; 'j&ac*t:i'Q 
:-': 'v.'-i ,0 ^r'/cX o.}” tjii‘tsjq ovofj •{} 
.;,no'l 9:t3i'iqi^0/?qo.'t(?.r 3i-i ot ^*?f*tiV^OO ai OT-d 
^•■^' i-. ■'-3^i-3'^'^s^Tivr>ccii'i6riqanrfq •ninjsvs-s/iirfSrtJBXoqtr< 
' .:, '\iOi:-oi.i: .Tonob Iy0d-.liro(iq9-.;'fq oa 
•' •'- ---‘•'"'U^ri^iqol: -.? “to ipvldiru''i 3Co8Jij»*')r'i’ii*/9aq oints^a 
■ i •34fi^jjq ovon ifi) .esai^l 
'’.. j^.'i^cnr stiavapo rfoinv qwi a^Jtoirffii 
’■• .- .■ ^ ... oais .^'^^tX)^*''^A oJU^Cfi^fXMx os 
.'iif . :-^)d>jai7i:.0 4H ::o,r<qcn^a *?ui>oei^‘r/rt y^d ^<32 ot <LMO to 
-.T^r:. . w .IpIK-.v ■'u.ir, 'Vo n0iJ'5lt>.‘nuoo-8 'r^iaale-i '^U ^i^oXlB 
•^X- ’ . ai/©wboaqbn*) cd aia#/!?nv;e pvoft 8i) 
!!:*/•' '^ . a^o-Dl's 0ixc.t0'"v,’J ailT «xXao.r-<Sf‘ni^ *!<« ’ 3a^5K# tXuow 
^■ •.* t vd rro:?Bvi^tc ■ 'ict ric.od oonio 
•#o •!»/af:XBoriX sJidfcri ,s.oX£rtiB e.^«o«X8iuifl 8 ai (s^fnia 
- \»3X or jjloa oinibonx 3l*T:svr;oo i(Mian8;jo*ibic-ri 
- «*ix / #'. 1^0 (''^'■ Tf * w * to „'*!oe^w»e>i<'; 8<t:j fbiba ttlxeis 
^vAnoami^ os a x.i^a^uSc/U^ysi ^,4 oS toot ftoW «j4 aXo* 
9i 9Jliocfc:*^v\ otjcitbt 8J-I .aX-.'o:?-* 8^1 (li ' 
- 'j-j.Cotrn ‘tot ftr^zr^^L'z s ad orr ax fl to ai^fflqtorfq-'^ j 
'i; s'a.-iv'aAfi i sjn-.i'iyq ovon bd'dJE#ioec s^losxrri^ * («Ui)t&aaiji «2)i8 j 
-'''‘!'ii J 
41 
to 39.1?^ of control. Inhibition of guanine nucleotide synthesis 
was twice as great as irihibition of adenine synthesis. In add¬ 
ition to reducing the guanine pools directly, virazole may also 
have decreased AMP synthesis because GTP is a necessary cofactor 
in the conversion of IMP to adenylosuccinic acid(SAMP), the 
precursor of AMP. With both AMP and GMP synthesis decreased 
by virazole, the precursor IMP builds up and further decreases 
de novo purine synthesis by feedback inhibition of amidophos- 
phoribosyl transferase(24) and PRPP synthetase(45). This in¬ 
hibition of PRPP synthetase would result in decreased FUra 
activation making virazole and FUra an antagonistic sequential 
combination of agents. 
Other Anti-Tumor Agents 
PALA(N-phosphonacetyl-L-aspartate) is a transition 
state analog inhibitor of L-aspartate transcarbamoylase, the 
enzyme catalyzing the first committed step in de novo pyrimi¬ 
dine synthesis. Treatment with PALA leads to decreased pyrimi¬ 
dine ribonucleotide and deoxyribonucleotide pools and to a 
marked decrease in orotate synthesis(30)• The reduced pyrimi¬ 
dine nucleotide levels limit DNA and RNA synthesis and purine 
nucleotides accumulate due to decreased utilization. PALA 
may interfere with de novo purine synthesis(85^ of control) 
indirectly as the elevated purine levels reduce de novo purine 
synthesis by feedback inhibition. The reduced orotate levels 
would enhance the activation of FUra to FUMP because FUra 
competes with orotate which is the preferred substrate for 
orotate phosphoribosyltransferase(9)= 
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Hydroxyurea inhibits ribonucleoside diphosphate re¬ 
ductase leading to reduced' deoxynucleotide triphosphate pools 
and therefore to reduced DNA synthesis(46), Hydroxyurea 
produces increased levels of ADP and GDP which feedback and 
inhibit amidophosphoribosyl transferase(24,45)i thus decreas¬ 
ing de novo purine synthesis. In this study hydroxyurea was 
found to decrease de novo purine synthesis only to 90fo of 
control. Hydroxyurea would be expected to partially antag¬ 
onize the effects of FUra by blocking the conversion of FUDP 
to FdUDP and therefore to the active metabolite, FdUMP, a re¬ 
action catalyzed by ribonucleotide diphosphate reductase. (See 
Figure H) FUDP, however, would still be converted to FUTP and 
incorporated into RNA in the presence of hydroxyurea. It has 
been reported that hydroxyurea does partially block the activa¬ 
tion of FUra in Novikokk hepatoma cells (41 )<, 
Leukovorin(5“formyl-tetrahydrofolate) can be converted 
to 5fl0 methylene tetrahydrofolate within cells and therefore 
can rescue L1210 cells from the anti-purine and anti-thymi¬ 
dine effects of methotrexate(4?). As expected, leukovorin 
did not inhibit de novo purine synthesis, but rather, in¬ 
creased it slightly to 108,2^ of control, Leukovorin would 
not be expected to be synergistic with FUra as no increase 
in intracellular PRPP would result from pretreatment with 
leukovorin. 
Vincristine, a vinca alkaloid, binds with tubulin, the 
structural protein precursors of microtubules, preventing their 
assembly and inhibiting the mitotic spindle. Vincristine 
arrests mitosis in metaphase and the bound tubulin molecules 
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form intracellular, crystalline precipitates resulting in 
cell death and lysis(48). Following cell death, nucleic acid 
breakdown and purine salvage occur and the increased concen¬ 
trations of liberated purines decrease de novo purine synthesis 
by feedback inhibition. Vincristine was found to inhibit de 
novo purine synthesis to 15.2^ of control. No increase in 
intracellular PRPP would result from treatment with vincristine 
because the salvaged purines would inhibit PRPP synthetase as 
well as amidophosphoribosyl transferase. Therefore cytotoxic 
synergism resulting from sequential treatment with vincristine 
and FUra would be unlikely, 
Actinomycin D is an antibiotic which non-covalently 
complexes with DNA preventing its template function in trans¬ 
cription. Actinomycin D*s phenoxazone ring intercalates 
between two G-C base pairs blocking RNA chain elongation by 
RNA polymerase(49). The non-functional DNA-actinomycin D 
complexes are rapidly degraded producing increased intracell¬ 
ular ATP and GTP levels from DNA and RNA breakdown. The ele¬ 
vated nucleotide levels feedback and inhibit de novo purine 
synthesis regulating both amidopohsphoribosyl transferase and 
PRPP synthetase. In one study, a 50% reduction in intracell¬ 
ular PRPP levels was found after incubating Chinese Hamster 
cells with actinomycin D for 2 hours, suggesting feedback in¬ 
hibition by a measured two-fold increase in intracellular 
purine nucleotides(32), In this study actinomycin D was found 
to be a potent inhibitor of de novo purine synthesis, reducing 
the rate to 8.7% of control. With the lowered PRPP levels that 
actinomycin D induces, less FUra would be converted to the 
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metabolically active fluoro-nucleotides. 
Cycloheximide is a protein synthesis inhibitor which 
binds to ribosomal RNA inhibiting the peptidyl transferase 
activity of the 60S ribosomal subunit(50). These faulty RNA 
molecules are rapidly degraded and the liberated purines are 
salvaged. As with actinomycin D, de novo purine synthesis is 
inhibited by these nucleotides made available by nucleic acid 
catabolism. Cycloheximide decreased de novo purine synthesis 
to 10.9^ of control in this stud>. Taylor et al. found a 50% 
reduction in PRPP levels following a 2 hour incubation with 
cycloheximide and a concomitant two-fold increase in purine 
nucleotides(32). Pretreatment of cultures with cycloheximide 
would antagonize the effects of FUra because the decreased PRPP 
levels would decrease activation of FUra, 
De Novo Purine Synthesis in relation to Cell Culture Density 
Studies examining the rate of de novo purine synthesis 
along the growth curve of L1210 cells revealed that the rate 
of de novo purine synthesis decreased steadily with increas¬ 
ing cell culture density, even during the exponential phase 
of growth. Possible causes for this decline in de novo purine 
synthesis in the face of logarithmic cell growth include: 
1) increased salvage purine synthesis secondary to either 
14 
decreased availability of 1- C-glycine in older, more popu¬ 
lated cultures or to increased salvage pathway substrate 
availability, 2) a decreased rate of de novo purine synthesis 
secondary to a lengthening of the cell cycle along the growth 
curve, and 3) decreasing cell volume with less purine and 
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pyrimidine synthesis required to maintain stable intracellular 
nucleotide concentrations. The observed decrease in de novo 
purine synthesis along the growth curve represents a rate 
measurement because cell cultures at varying densities were 
14 
each incubated with 1- C-glycine for 2 hours before the 
amount of newly synthesized adenine and guanine was quantitated. 
Because the cell cultures were growing logarithmically during 
this study, the total amount of purine synthesis was necessarily 
increasing as the cell culture density increased along the 
growth curve. 
One explanantion for the decrease in de novo purine 
synthesis in the face of logarithmic culture growth is that 
salvage purine biosynthesis is supplying increasing amounts of 
purine nucleotides with increasing culture density. It was 
14 
demonstrated above that the amount of intracellular 1- C- 
glycine per 10 cells in old and new cultures with densities 
of 3*8 X 10-^cells/cc and 9.0 X lO^cells/cc, respectively, after 
14 
a 24-hour incubation with 1- C-glycine was not significantly 
different. Therefore, decreasing availability of this radio¬ 
active substrate at higher culture densities could not account 
for the observed decline in de novo purine synthesis. 
Increasing concentrations of exogenous hypoxanthine in 
the culture media led to a steady decrease in de novo purine 
synthesis, and with increasing concentrations of exogenous 
14 . . 
C-hypoxanthine, proportionately greater amounts of adenine 
14 
and guanine were synthesized from C-hypoxanthine. These 
results reveal that L1210 cells possess hypoxanthine-guanine 
phosphoribosyltransferase, the purine salvage enzyme, and that 
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hypoxanthine is the preferred substrate for purine synthesis. 
Given the choice, L1210 cell cultures will utilize the salvage 
rather than the de novo pathway for purine biosynthesis. The 
Kjyj of rat liver hypoxanthine-guanine phosphoribosyltransferase 
for PRPP is 5uM(52) and of adenine phosphoribosyltransferase is 
6uM(53). This contrasts with Kj^ values of mammalian amidophos- 
phoribosyl transferase for PRPP of 86-600uM(54). Thus the 
salvage pathway may inhibit de novo synthesis not only by 
endproduct inhibition of amidophosphoribosyl transferase and 
PRPP synthetase, but also by preferential utilization of PRPP. 
In order for the purine salvage pathway to become in¬ 
creasingly active during logarithmic growth, cell death with 
reutilization of nucleic acids must also increase proportion¬ 
ately during log growth. The viability of L1210 suspension 
cultures as tested by trypan blue exclusion was found to be 
99% during exponential growth. After 120 hours of growth in 
culture, viability was reduced to C 70%i7), It has been sug¬ 
gested that since cell lysis rapidly follows cell death, the 
trypan blue exclusion test may not accurately measure the 
total amount of cell death(55). But even if the percentage 
of dying cells was slightly greater than \% during log 
growth, it is unlikely that enough cell death and subsequent 
purine salvage could occur during the log phase to compen¬ 
sate for the observed decrease in de novo purine synthesis to 
20% of control. In a suspension culture of human lymphoid 
cells, the percentage of cells in S phase, actively synthesiz¬ 
ing DNA, was 50% during exponential growth(55). Thus much 
more than 1% of the cells would have to undergo lysis along the 
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growth curve to allow the salvage pathway to significantly con¬ 
tribute to purine synthesis during log growth. During plateau 
phase growth, however, in a cell culture that is not nutrition¬ 
ally depleted, the percentage of cells in S phase is equal to 
the percentage of dying cells, thus maintaining the plateau 
phase steady state(55). In this situation, the salvage pathway 
of purine synthesis would be expected to substantially contrib¬ 
ute to total purine biosynthesis, 
A second possible explanation for the reduced rate of 
de novo purine synthesis during logarithmic growth is elonga¬ 
tion of the cell cycle resulting in a slower overall rate of 
de novo synthesis, not necessarily accompanied by a decrease 
in total de novo purine synthesis. The cell cycle is defined 
as the interval between the midpoint of mitosis and the mid¬ 
point of the subsequent mitosis of one or both daughter cells 
(56). It has been found that the control of population growth 
in a cell culture may be due to nutritional deficiency or to 
cell-cell interactions and density inhibition(55»5^), Holly 
and Kiernan demonstrated that the concentration of serum in 
culture media determined the final saturation density of 
cultured cells(57). fen et al,, however, have shown that for 
human lymphoid cells in suspension cultures at a concentration 
of 6,5-7.0 X lO^cells/cc, no increment in serum concentration 
would stimulate continued culture growth. This shows that at 
7 X lO^cells/cc, culture density becomes the growth limiting 
mechanism for human lymphoid cells(55). L1210 cultures passing 
through the exponential and plateau phases of growth in the 
inoculate®s original media, are likely growth regulated by both 
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inhibitory mechanisms. The cells of cultures in which nutri¬ 
tional deficiencies develop over time progressively accumulate 
in the phase of the cell cycle(55»58), the interval between 
completion of mitosis and the onset of DNA synthesis(56). 
Rossow et al. have proposed that during C-^, an intracellular 
protein (R) is synthesized and when accumulated in sufficient 
quantities, allows for the initiation of DNA synthesis and for 
the completion of the cell cycle(58). Serum growth factors 
are believed to induce this "initiator protein". Thus in 
nutritionally depleted cultures, cells build up in an elonga¬ 
ted G^ phase presumably because more time is required for the 
initiator protein concentration to reach the critical levels. 
During logarithmic growth, the nutritive serum factors are 
gradually consumed resulting in elongated G^ phases and thus 
in a lengthening of the cell cycle along the growth curve. As 
increasing numbers of cells accumulate in the G^ phase, a de¬ 
creasing percentage of cells will be synthesizing DNA (S phase) 
as logarithmic growth progresses. This gradual decrease in 
the percentage of S phase cells along the growth curve has 
been demonstrated by many investigators(11,59). In L1210 
suspension cultures, thymidine labelling indices decline 
nearly 10-fold throughout exponential and plateau phases of 
growth(ll). This decreasing percentage of S phase cells 
coupled with a lengthening cell cycle offers an explanation 
for the observed decreased rate of de novo purine synthesis 
in the face of exponential cell culture growth. Per unit time, 
fewer and fewer cells will be actively involved in de novo 
purine synthesis as logarithniic grov.’th progresses, although 
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the total amount of de novo purine synthesis will increase as 
culture doublings continue along the growth curve. Hahn et al. 
observed a gradual lengthening of the cell cycle in Chinese 
Hamster cells with 15 hours being the average cell cycle for 
early log phase cells and J>2 hours the average cycling time 
for plateau phase cells(60), The growth curve for L1210 cells 
in Figure B demonstrates this elongation of the cell cycle 
with 10, 22 and') 44 hours being required for successive cell 
culture doublings during exponential and plateau phase growth. 
A third phenomenon possibly contributing to the explan¬ 
ation for the decreased rate of de novo purine synthesis during 
logarithmic growth is a progressive decrease in cell volume 
along the growth curve thereby requiring fewer nucleotides per 
cell to maintain constant nucleotide concentrations. If cell 
volume gradually decreased, less total purine synthesis would 
have to occur to supply a growing culture of smaller cells with 
the purines needed to achieve the appropriate nucleotide concen¬ 
trations. Yen et al. demonstrated that the cells in nutrition¬ 
ally limited cultures gradually accumulate in and that their 
volumes progressively diminish(55)• C. Benz et al. showed that 
in L1210 suspension cultures, cell volumes decrease throughout 
the mid log, late log and plateau phases of growth, being 
reduced to 60fo of their initial volumes by the late log and 
plateau phases(7). Scanning electron microscopy of these smaller 
cells revealed them to be of G^/G^ appearance with loss of 
surface microvilli(6l). Benz et al. also demonstrated a pro¬ 
gressive decrease in intracellular deoxynucleotide triphosphate 
pools/lO^ cells with increasing culture density, reflecting the 
need for reduced nucleotide pools with decreasing cell volume(7). 
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De novo purine synthesis will decraese in response to the need 
for reduced nucleotide pools which develop as cell volumes 
decrease during log growth. 
In examining possible causes for the decreased rate of 
de novo purine synthesis throughout log and plateau phase 
growth, it seems likely that increased salvage pathway purine 
synthesis, elongation of the cell cycle resulting in fewer S 
phase cells per unit time, and decreased cell volume along the 
growth curve all contribute to the reduced rate of de novo syn¬ 
thesis. Given that the rate of de novo purine synthesis in late 
log phase has decreased to^ 205^ of its early log phase value, 
the anti-purine effects of an anti-tumor agent must be inter¬ 
preted keeping this natural decrease in mind. As seen in 
Table 2, methotrexate's anti-purine effects could be underestim¬ 
ated if tested only with late log phase cells; methotrexate 
is a very potent anti-purine agent when incubated with early 
log cells which are synthesizing larger quantities of purines 
per unit time. Conversely, the anti-purine effects of a weakly 
inhibitory anti-tumor agent could be overrated if tested with 
late log phase cells which have decreased rates of de novo 
purine synthesis for reasons unrelated to the cytotoxic agento 
The anti-purine effects of drugs, therefore, must be studied 
utilizing control cultures with nutritional states and culture 
densities identical to those of the experimental cultures. 
5-fluorouracil exhibits cytotoxic synergism with anti¬ 
purine agents which elevate intracellular levels of PRPP re¬ 
sulting in enhanced metabolic activation of the fluoropyrimi- 
dine. The synergism between, for example, methotrexate and 
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FUra, however, is related to the anti-purine potency of metho¬ 
trexate because the degree of PRPP level elevation is propor¬ 
tional to the magnitude of methotrexate’s inhibition of de 
novo purine synthesis(9). Because intracellular PRPP levels 
also decrease during log growth paralleling the rate of de novo 
purine synthesis, the synergism between methotrexate and FUra 
would be blunted if methotrexate were incubated with a late 
log culture in which the rate of de novo purine synthesis 
was only 20% of the maximal early log rate.(7) Similarly, the 
synergistic effects of sequential treatment with methotrexate 
and FUra seen with early log phase cultures in vitro would 
probably not be as apparent when tested against a solid tumor 
mass in vivo, the center of which contains cells in the 
resting phase due to hypoxia and nutrient depletion(62). The 
cell cycle kinetics of these resting tumor cells are more 
comparable to those of plateau phase cells in a nutrient- depleted 
culture and it is likely that the rate of de novo purine syn¬ 
thesis within this cell population would not be substantial 
enough to allow for marked inhibition by methotrexate. With 
methotrexate powerless to significantly inhibit low baseline 
levels of de novo purine synthesis in slowly cycling tumor 
cells, the already low baseline levels of PRPP would be ele¬ 
vated only slightly and the basis for the synergism between 
methotrexate and FUra would be undermined. 
On the other hand, several investigations have re¬ 
vealed that some malignant tumors have an increased capacity 
for de novo purine synthesis. Measurments of amidophospho- 
ribosyl transferase in rat hepatomas demonstrated a 2 to 4-fold 
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increase in activity compared to normal rat liver(63). This 
increased enzyme activity was found even in well-differentiated 
hepatomas with slow growth rates. Increased amidophosphorihosyl 
transferase activity has also been observed in transplantable 
rat kidney tumors relative to normal kidney cortex(64). AICAR 
(aminoimidazolecarboxamide ribonucleotide) transformylase and 
adenylosuccinate lyase, two other enzymes of the de novo purine 
synthesis pathway, have also been shown to have increased activ¬ 
ity in rat hepatomas as compared to controls(65,66), Some 
malignant tumors, therefore, appear to have an increased capa¬ 
city for de novo purine biosynthesis and, like early log phase 
cells in vitro, would likely be strongly inhibited by anti¬ 
purine agents and by sequential methotrexate-5-fluorouracil 
chemotherapy. 
In summary, it has been shown that many anti-tumor 
agents with widely varying mechanisms of action have the abil¬ 
ity to inhibit de novo purine synthesis. Even agents which 
do not directly interfere with the de novo purine synthesis 
pathway can profoundly affect purine biosynthesis. It is 
hoped that this knowledge of the anti-purine effects of the 
cytotoxic agents will be useful to other investigators in¬ 
volved in designing biochemically rational combination 
chemotherapy. 
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